SCTX

12.1608.02%
BT

Brett T. Staahl

Co-Founder & VP of External Innovation

Mr. Brett T. Staahl Ph.D., is the Co-Founder at Scribe Therapeutics Inc. and serves as its Vice President of External Innovation from April, 2023. He served as Vice President of Platform at Scribe Therapeutics Inc. until April 2023. Previously, he was a Postdoctoral Fellow in the lab of Jennifer Doudna where he pioneered the use of CRISPR ribonucleoproteins, developed robust methods to deliver the proteins to various cell types both in vivo and ex vivo and showed how they could safely and effectively be used to inactivate disease-causing genes and slow neurodegeneration. He has over 20 scientific publications in top-tier journals, several patents issued and pending and received numerous research grants and awards including the F. Hoffmann-La Roche Postdoctoral Fellowship. Prior to completing his postdoctoral work at the University of California, Berkeley, he received his B.S. in Molecular, Cellular and Developmental Biology from the University of Colorado, Boulder and his Ph.D. in Developmental Biology from Stanford University, where he studied the genetic circuitry underlying development of the mammalian nervous system and discovered de novo function-altering mutations in the genes of sporadic Amyotrophic Lateral Sclerosis (ALS) patients.

Positions